Skip to Main content Skip to Navigation
Journal articles

Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study

Clément Bailly 1, 2 Thomas Carlier 2, 1 Bastien Jamet 1 Thomas Eugène 1 Cyrille Touzeau 3 Michel Attal 4 Cyrille Hulin 5 Thierry Facon 6 Xavier Leleu 7 Aurore Perrot 8 Laurent Garderet 9 Margaret Macro 10 Denis Caillot 11 Philippe Moreau 12, 13 Francoise Kraeber-Bodere 2, 1, 14 Caroline Bodet-Milin 2, 1, *
* Corresponding author
1 Service de Médecine Nucléaire [Nantes]
2 CRCINA-ÉQUIPE 13 - Nuclear Oncology
CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
3 CRCINA-ÉQUIPE 10 - Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma
CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
4 Département d'Hématologie [IUCT Oncopole, Toulouse]
5 Département d'Hématologie [CHU Haut Lévèque, Pessac]
6 Département d'Hématologie [CHRU Lille]
7 Département d'Hématologie [CHU Poitiers]
8 Département d'Hématologie [CHRU Nancy]
9 Département d'hématologie [CHU Saint-Antoine, AP-HP]
10 Laboratoire d'Hématologie Biologique [CHU Caen]
11 Département d'hématologie [CHU Dijon]
12 CRCINA-ÉQUIPE 11 - Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression
CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
13 Département d'Hématologie [CHU Nantes]
14 Département de Médecine Nucléaire [Saint Herblain]
Abstract : Purpose: To assess the prognostic value of interim 18 F-fluorodeoxyglucose (FDG)-PET analysis using decrease in maximum standardized uptake value (SUVmax) versus visual analysis in patients with multiple myeloma. Patients and Methods: We evaluated the prognostic value of FDG-PET after three cycles of lenalidomide, bortezomib, and dexamethasone (RVD) in patients with FDG-avid multiple myeloma included in the French prospective multicenter IMAJEM study. All images were centrally reviewed and interpreted using visual criteria and maximal standardized uptake value reduction (DSUVmax). Known prognostic factors, such as the revised International Staging System and biochemical response after three cycles of chemotherapy, were also evaluated. Results: In the multivariate analysis, only DSUVmax [P < 0.001, HR ¼ 5.56; 95% confidence interval (CI), 1.96-15.81] and biochemical response after three cycles of RVD (P ¼ 0.025, HR ¼ 0.29; 95% CI, 0.1-0.85) appeared as independent prognostic factors, with a more discriminative HR for DSUVmax. DSUVmax analysis (>-25% vs.-25%) identified patients with improved median progression-free survival (22.6 months and not reached, respectively). Conclusions: DSUVmax appears to be a powerful tool for the prediction of long-term outcome in patients with FDG-avid multiple myeloma. Other prospective studies are needed to further validate this prognostic biomarker.
Document type :
Journal articles
Complete list of metadatas

Cited literature [24 references]  Display  Hide  Download
https://www.hal.inserm.fr/inserm-01934540
Contributor : Elizabeth Bernardo <>
Submitted on : Monday, November 26, 2018 - 9:20:33 AM
Last modification on : Sunday, October 25, 2020 - 7:04:24 AM
Long-term archiving on: : Wednesday, February 27, 2019 - 12:56:29 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

CNRS | UNIV-ANGERS | COMUE-NORMANDIE | CRCINA | UNIV-NANTES | UNICAEN | LNC-UMR866 | UNIV-BOURGOGNE | LNC-SAPHIHR | POLITIQUES-PUBLIQUES

Citation

Clément Bailly, Thomas Carlier, Bastien Jamet, Thomas Eugène, Cyrille Touzeau, et al.. Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study. Clinical Cancer Research, American Association for Cancer Research, 2018, 24 (21), pp.5219 - 5224. ⟨10.1158/1078-0432.ccr-18-0741⟩. ⟨inserm-01934540⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

218